This particular patent states that infant formula is a risk for long-term
damage of the kidneys and liver.  This is patent # 5739407 called, "Human
.beta-casein, process for producing it and use thereof."  The owner is Bergstrom et
al. and the assignee is Symbicom aktiebolag.  It was filed in 1993.  It states
that the main use of recombinant human .beta-casein is as a constituent of
infant formula.
Valerie W. McClain, IBCLC

"In spite of the great efforts which have been invested in preparing infant
formulae, it has not been possible to produce a formula which to any
substantial extent has the advantageous properties of human milk. Thus, infant formula,
often prepared on the basis of cow milk, is generally incompletely digested by
the infant and is lacking substances known to have effect on the
physiological functions of the infant. In order to obtain an infant formula with a
nutritional value similar to human milk, a number of additives including protein
fragments, vitamins, minerals etc., which are normally formed or taken up during
the infant's digestion of human milk, are included in the formula with the
consequent risk of posing an increased strain on and possible long-term damage of
important organs such as liver and kidney. Another disadvantage associated
with the use of cow milk-based formulae is the increased risk for inducing
allergy in the infant against bovine proteins."



             ***********************************************

To temporarily stop your subscription: set lactnet nomail
To start it again: set lactnet mail (or digest)
To unsubscribe: unsubscribe lactnet
All commands go to [log in to unmask]

The LACTNET mailing list is powered by L-Soft's renowned
LISTSERV(R) list management software together with L-Soft's LSMTP(TM)
mailer for lightning fast mail delivery. For more information, go to:
http://www.lsoft.com/LISTSERV-powered.html